1. Should We Dry the Retina Faster for Longer
Should We Dry the Retina Faster for Longer? Comparing Anatomical Outcomes in nAMD

3. Program Introduction

4. Relevance of Morphological Responses to anti-VEGF Treatment

5. FLUID Study: OCT SRF Fluid Determination

6. Outcomes in Eyes with RAP in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)

7. Results from CATT Trial: IRF

8. FLUID Study: Mean Change in BCVA

9. Identifying Fluid vs Degenerative Changes

10. BCVA Change from Baseline to Week 96: brolucizumab vs aflibercept

11. In HAWK and HARRIER, Fewer Patients on brolucizumab had IRF and/or SRF Fluid at Weeks 16, 48 and 96

12. In HAWK and HARRIER, Fewer Patients on brolucizumab had sub-RPE Fluid at Weeks 16, 48 and 96

13. Advantages of Using an Agent With Longer Durability (ie, brolucizumab)

14. Over 75% of brolucizumab 6 mg Patients who Completed Week 48 on a q12w Interval Remained on q12w Interval until Week 96

15. Patient Sustained Drying of Retina with 10 Injections (brolucizumab 6 mg) Over 2 Years After Loading Dose

16. HAWK and HARRIER Demonstrated Less Disease Activity at Week 16 with brolucizumab Compared to aflibercept

17. Brolucizumab Achieved Superior Reductions in CST From Baseline to Week 16 and Week 48; this Difference was Maintained at Week 96

18. The LADDER Trial: Initial Study Results

19. The Significance of Drying the Retina at an Early Timepoint: Panelist Viewpoints

20. Long-Term Maintenance of VA Results

21. 5-Year CATT Results: Mean VA

22. The Impact of More Durable Treatments

23. Abbreviations